Osteoporosis is a metabolic disease characterized by decreased bone mass and density that unavoidably lead to bone fragility and increased incidence of fractures.
Our Preclinical Testing Tools
The TghRANKL mouse model spontaneously develops osteoporosis pathology from the first weeks of age with 100% penetrance due to the overexpression of human RANKL.
Osteoporosis Preclinical Evaluation Platform
TghRANKL mice treated from week 4-10 of age with standardized denosumab regimens show complete osteoporosis remission.
TRAcP serum levels measurements as a marker of osteoclast activity
Histopathological evaluation of femur sections
μCT analysis of femurs and evaluation of trabecular and cortical bone morphology
Human RANKL driven osteoporosis
TghRANKL mice develop spontaneous osteoporosis pathology and can be effectively treated from 4-10 weeks of age with a range of doses of anti-human RANKL biologics .
TghRANKL osteoporosis model efficiently recapitulates human osteoporosis pathology and in combination to standardized evaluation procedures it offers the opportunity for reliable evaluation of the efficacy of anti-human RANKL biologics and denosumab biosimilars as well as novel osteoporosis treatments.